Skip to content

Cost-Effectiveness of Blood Transfusion Alternatives

Hematology

Restrictive blood transfusion practices are associated with improved patient outcomes. (opens new window)

Goodnough LT, Maggio P, Hadhazy E, Shieh L, Hernandez-Boussard T, Khari P, Shah N.

Source‎: Transfusion 2014;54(10 Pt 2):2753-9.

Indexed‎: PubMed 24995770

DOI‎: 10.1111/trf.12723

https://www.ncbi.nlm.nih.gov/pubmed/24995770 (opens new window)

Recombinant activated factor VII use in critically ill infants with active hemorrhage. (opens new window)

Jen H, Shew S.

Source‎: J Pediatr Surg 2008;43(12):2235-8.

Indexed‎: PubMed 19040942

DOI‎: 10.1016/j.jpedsurg.2008.08.053

https://www.ncbi.nlm.nih.gov/pubmed/19040942 (opens new window)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (opens new window)

Kaur MN, Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Carruthers J, Li N, Liu Y, Xie F

Source‎: Blood Adv. 2022;6(3):785-92.

Indexed‎: PubMed 34781363

DOI‎: 10.1182/bloodadvances.2021005627

https://pubmed.ncbi.nlm.nih.gov/34781363/ (opens new window)

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (opens new window)

Lightdale JR, Randolph AG, Tran CM, Jiang H, Colon A, Houlahan K, Billet A, Sloan S, Lehmann LE.

Source‎: Biol Blood Marrow Transplant 2012;18(5):813-7.

Indexed‎: PubMed 22080050

DOI‎: 10.1016/j.bbmt.2011.10.043

https://www.ncbi.nlm.nih.gov/pubmed/22080050 (opens new window)

The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (opens new window)

McQuilten ZK, Higgins AM, Burns K, Chunilal S, Dunstan T, Haysom HE, Kaplan Z, Rushford K, Saxby K, Tahiri R, Waters N, Wood EM.

Source‎: Transfusion 2019;59(11):3386-95.

Indexed‎: PubMed 31664712

DOI‎: 10.1111/trf.15558

https://www.ncbi.nlm.nih.gov/pubmed/31664712 (opens new window)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (opens new window)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Source‎: Transfusion 2015;55(12):2807-15.

Indexed‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (opens new window)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (opens new window)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Source‎: Cancer 2013;119(1):107-14.

Indexed‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (opens new window)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (opens new window)

Nikolaidi E, Hatzikou M, Geitona M.

Source‎: Cost Eff Resour Alloc 2013;11(1):16.

Indexed‎: PubMed 23870502

DOI‎: 10.1186/1478-7547-11-16

https://www.ncbi.nlm.nih.gov/pubmed/23870502 (opens new window)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (opens new window)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Source‎: Support Care Cancer 2012;20(1):159-65.

Indexed‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (opens new window)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (opens new window)

Ravangard R, Mirzaei Z, Keshavarz K, Haghpanah S, Karimi M.

Source‎: Hematology 2018;23(7):417-22.

Indexed‎: PubMed 29157136

DOI‎: 10.1080/10245332.2017.1404262

https://www.ncbi.nlm.nih.gov/pubmed/29157136 (opens new window)

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (opens new window)

Reitan JF, Kudrik FJ, Fox K, van Breda A, Shreay S, Corey-Lisle PK.

Source‎: J Med Econ 2013;16(5):633-8.

Indexed‎: PubMed 23425291

DOI‎: 10.3111/13696998.2013.778269

https://www.ncbi.nlm.nih.gov/pubmed/23425291 (opens new window)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (opens new window)

Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C.

Source‎: Transfusion 2010;50(2):487-92.

Indexed‎: PubMed 19804569

DOI‎: 10.1111/j.1537-2995.2009.02413.x

https://www.ncbi.nlm.nih.gov/pubmed/19804569 (opens new window)

Increased hospital costs associated with red blood cell transfusion. (opens new window)

Trentino KM, Farmer SL, Swain SG, Burrows SA, Hofmann A, Ienco R, Pavey W, Daly FF, Van Niekerk A, Webb SA, Towler S, Leahy MF.

Source‎: Transfusion 2015;55(5):1082-9.

Indexed‎: PubMed 25488623

DOI‎: 10.1111/trf.12958

https://www.ncbi.nlm.nih.gov/pubmed/25488623 (opens new window)

COST-EFFECTIVENESS OF BLOOD TRANSFUSION ALTERNATIVES
Hematology
English
Hematology
https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Hospital Liaison Committee (HLC)

Contact local representatives who provide free assistance to clinicians treating Jehovah’s Witnesses.

Contact

Medical Information Packets

Subjects include: Clinical strategies for managing hemorrhage and anemia without blood transfusion, the religious and ethical position of Jehovah’s Witnesses on medical therapy, and the services Witnesses offer to the medical community through their worldwide network of Hospital Liaison Committees.

View Downloads

Videos

Treatment options as well as medical and ethical considerations for clinicians who treat Jehovah’s Witnesses.

View Videos